Sep 2026· World Journal of Pediatrics· Vol 22, pp. 1083 - 1094· 0 citations· 56 references
Medicine
TL;DR
This is the first report on the incidence and survival of children with pLGG in Switzerland, and children with pLGG have an excellent long-term survival rate of over 90%.
Abstract
Brain tumors are the most common solid cancers occurring in children, with pediatric low-grade gliomas (pLGG) being the most frequent central nervous system (CNS) tumors in children. The overall survival of pLGG is excellent, with a ten-year survival of 85%–96%. Prognostic factors include age, gender, anatomical location, and histological and molecular subtype. Despite the excellent survival rates, children suffering from pLGG often have a diminished quality of life due to functional or neurologic deficits either caused by the primary tumor or as a side effect of their treatment. In this study, we describe the epidemiology of pLGG in Switzerland. The target population comprised children aged 0–17 years, diagnosed with histologically verified pLGG during 1990–2019 while residing in Switzerland. We retrieved the data from the Swiss Childhood Cancer Registry (ChCR). We calculated crude incidence rates per 100,000 person-years and observed survival (OS) using the Kaplan-Meier estimator (non-parametric univariable analysis). We estimated OS separately according to age histological subgroup and treatment group. We included 591 pLGG during 1990–2019 in Switzerland. Most pLGG were diagnosed at the age of 2–11 years (n = 352, 59.6%). Around half of pLGG were supratentorial located (n = 286, 48.4%), while the other half (n = 266, 45.0%) occurred infratentorial. Most pLGG (82.0%) were World Health Organization (WHO) grade 1. The vast majority of pLGG (n = 501, 84.8%) were treated with surgery, either alone (n = 441, 74.6%) or in combination with other treatments. The lowest 5- and 10-year survival was observed in children who received surgery followed by radiotherapy and/or chemotherapy (40% and 20%). Astrocytoma excluding pilocytic astrocytoma had a significantly lower 5-year, 10-year and total survival (98.8%, 85.8%, and 82.1%) compared to the other histopathological subtypes (P = 0.024). This is the first report on the incidence and survival of children with pLGG in Switzerland. Children with pLGG have an excellent long-term survival rate of over 90%.
Currently, there are no universal adjuvant chemotherapy agents, so the latest advances in genomic and epigenomic research of meningiomas are being explored for potential targeted therapy.
A. Rynda, V. Olyushin, D. Rostovtsev et al.· MD-Onco· 0 citations
BACKGROUND
Central nervous system (CNS) tumors in infants are rare, pose unique clinical challenges, and lack large-scale evidence-based data to guide management. This study seeks to describe CNS tumors in Canadian infants and to compare their outcomes with those of older children.
METHODS
We conducted a retrospectiv...
Samuel Sassine, Hallie Coltin, Sylvia Cheng et al.· Pediatric Blood & Cancer· 0 citations
INTRODUCTION
Primary breast sarcoma (PBS) accounts for approximately 1% of all breast malignancies. Research in pediatric, adolescent, and young adult (AYA) populations is limited and often based on large national databases. This study aims to characterize clinical presentation, treatment patterns, and outcomes of PBS...
A. Perrier, Alexander D. Lee, Heather A. Lillemoe et al.· Journal of Surgical Research· 0 citations
The near-absence of molecular results means the large majority of diffuse gliomas cannot be fully classified by current WHO standards, a concrete diagnostic-capacity gap with direct implications for prognostication, treatment stratification, and trial eligibility.
Suleiman S. Daoud, Atef F. Hulliel, Sultan Jarrar et al.· Frontiers in Oncology· 0 citations
Pediatric low-grade glial, glioneuronal, and neuronal tumors are a heterogeneous group with distinct clinicopathological features and supports the need for larger multicenter studies.
Meriem Boubekri, N. Cherradi· Child's Nervous System· 0 citations
Clinical factors combined with genomic and transcriptomic insights can improve relapse-risk identification, patient stratification, and therapeutic target discovery in relapsed WT and tRCC, demonstrating how clinical factors combined with genomic and transcriptomic insights can improve relapse-risk identification, pati...
Alissa Groenendijk· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.